07:00 , Jun 6, 2011 |  BC Week In Review  |  Company News

Merck KGaA sales and marketing update

Merck's EMD Serono Inc. division launched Cyanokit hydroxocobalamin in Canada to treat cyanide poisoning. Cyanokit is a precursor of vitamin B12. Terms were not disclosed. Merck KGaA (Xetra:MRK), Darmstadt, Germany   Business: Other  ...
07:00 , Apr 12, 2010 |  BC Week In Review  |  Company News

Swedish Oprhan Biovitrum, Merck KGaA sales and marketing update

The companies added Ireland, the U.K. and the Netherlands to the territories in which Swedish Orphan Biovitrum distributes Merck's Cyanokit hydroxocobalamin. The precursor of vitamin B12 is approved to treat cyanide poisoning. Swedish Orphan Biovitrum...
08:00 , Nov 2, 2009 |  BC Week In Review  |  Company News

King, Merck KGaA sales and marketing update

Merck's Merck Sante S.A.S. subsidiary granted King exclusive rights to commercialize Cyanokit hydroxocobalamin in the U.S., where it is approved to treat known or suspected cyanide poisoning. King said Cyanokit is a good fit for...
07:00 , Mar 24, 2008 |  BC Week In Review  |  Company News

Merck KGaA sales and marketing update

Merck KGaA's Merck Serono S.A. subsidiary launched Cyanokit hydroxocobalamin to treat known or suspected cyanide poisoning in Japan. The vitamin B12 precursor is marketed in the U.S. and approved in the EU for the same...
08:00 , Dec 3, 2007 |  BC Week In Review  |  Clinical News

Cyanokit hydoxocobalamin regulatory update

The EC approved an MAA for Cyanokit hydroxocobalamin to treat known or suspected cyanide poisoning in both adults and children. The precursor of vitamin B12 already is approved in the U.S. and Japan for the...
07:00 , Oct 1, 2007 |  BC Week In Review  |  Clinical News

Cyanokit hydoxocobalamin regulatory update

EMEA's CHMP issued a positive opinion for Cyanokit hydoxocobalamin to treat known or suspected cyanide poisoning. The vitamin B12 precursor is approved in the U.S. for the same indication. Merck KGaA (FSE:MRK), Darmstadt, Germany  ...
07:00 , Apr 2, 2007 |  BC Week In Review  |  Company News

Merck KGaA sales and marketing update

MRK's Dey L.P. subsidiary launched its Cyanokit 5 g Antidote hydroxocobalamin to treat cyanide poisoning in the U.S. Merck KGaA (FSE:MRK), Darmstadt, Germany   Business: Other  ...
08:00 , Jan 1, 2007 |  BC Week In Review  |  Clinical News

Cyanokit hydoxocobalamin regulatory update

FDA approved an NDA for Cyanokit hydroxocobalamin to treat known or suspected cyanide poisoning. Merck's Dey LP subsidiary will market Cyanokit in the U.S. and expects to launch the product early this year. Merck KGaA...
08:00 , Jan 1, 2007 |  BioCentury  |  Finance

4Q approvals

4Q approvals 4Q approvals Selected fourth quarter product approvals. Does not include the approvable letter for Vyvanse lisdexamfetamine (formerly NRP104) to treat pediatric ADHD from New River (NRPH) and Shire (LSE:SHP; SHPGY). While not a...
07:00 , Jun 26, 2006 |  BC Week In Review  |  Clinical News

Cyanokit hydoxocobalamin regulatory update

MRK's subsidiary EMD Pharmaceuticals Inc. (Durham, N.C.) submitted an NDA to the FDA for Cyanokit to treat known or suspected cyanide poisoning. The precursor of vitamin B12 has Fast Track designation in the U.S. Cyanokit...